Search - tctmd.com

Displaying 161 - 180 of 586

Sort: Relevancy | Date

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

Association Between CKD and Outcomes With Use of Prasugrel vs Clopidogrel in PCI for ACS

Presentation

Association Between CKD and Outcomes With Use of Prasugrel vs Clopidogrel in PCI for ACS

August 04, 2017

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

News Conference News EuroPCR 2017

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

June 02, 2017

Prasugrel, Ticagrelor and Clopidogrel in PPCI for STEMI: an analysis of comparative clinical outcomes from the UK BCIS national registry

Presentation EuroPCR 2017

Prasugrel, Ticagrelor and Clopidogrel in PPCI for STEMI: An Analysis of Comparative Clinical Outcomes from the UK BCIS National Registry

Presenter: Mamas A. Mamas

May 22, 2017

Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate

News Conference News EuroPCR 2017

Best Antiplatelet Therapy in Real-World PCI? European Registries Fuel the Debate

May 22, 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After ACS Saves Money, Prevents Bleeding

News Conference News EuroPCR 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

Yael L. Maxwell

May 16, 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

News Conference News EuroPCR 2017

EuroPCR 2017: New Stents, New Questions for PCI Today and Tomorrow as Angioplasty Turns 40

May 12, 2017

The Long and Short of It: DAPT Duration Choice After Stenting Gets Help From New Score

News Daily News

The Long and Short of It: DAPT Duration Choice After Stenting Gets Help From New Score

March 10, 2017

News Daily News

Multiple Antithrombotic Meds Before PCI in NSTE ACS Ups Bleeding Risk, Lowers Survival

Michael O'Riordan

December 13, 2016

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

November 14, 2016

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

Presentation TCT 2016

If Prolonged (>1 year) DAPT Is Chosen: Choosing Between Clopidogrel, Prasugrel and Ticagrelor

Presenter: John A. Bittl, Daniel I. Simon, C. Michael Gibson

October 30, 2016

News Daily News

EUCLID:替卡格雷相比氯吡格雷对有症状 PAD 患者预防心血管事件没有更大的好处

October 07, 2016

News Daily News

EUCLID: Ticagrelor Holds No Edge Over Clopidogrel for Preventing Atherothrombotic Events in Symptomatic PAD Patients

October 07, 2016

News Daily News

Ensayo EUCLID: Ticagrelor No es Más Beneficioso que Clopidogrel en la Prevención de Episodios CV en Pacientes con EAP Sintomática

October 07, 2016

News Daily News

Could E-Cigarettes Help People Quit Smoking? Study Suggests Yes

September 15, 2016

My Takeaways From ESC 2016: Eye-Rolling, Disappointments, and a Sobering Comeuppance

News Opinion Editor's Corner ESC 2016

My Takeaways From ESC 2016: Eye-Rolling, Disappointments, and a Sobering Comeuppance

September 08, 2016

PRAGUE-18 Study: Randomized Comparison Of Ticagrelor Versus Prasugrel In STEMI

Presentation ESC 2016

PRAGUE-18 Study: Randomized Comparison Of Ticagrelor Versus Prasugrel In STEMI

Presenter: Zuzana Motovska

August 30, 2016

News Conference News ESC 2016

Prasugrel, Ticagrelor Give Similar Short-term Outcomes After Primary PCI: PRAGUE-18

August 30, 2016

News Conference News ESC 2016

Platelet Function Testing to Guide Treatment Does Not Benefit Elderly ACS Patients: ANTARCTIC

August 28, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.